Device Trial Radar · NCT06491173
Detecting Traumatic Intracranial Hemorrhage With the InfraScanner 2500™ in Uganda
Last checked: Nov 20, 2026Latest source record: Feb 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
180
Actual
Start
Jul 30, 2024
Primary completion
Feb 28, 2025
Study completion Mar 30, 2025
Sponsor
- Lead sponsor
- Duke UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Mbarara Regional Referral Hospital; Mayanja Memorial Hospital
- First posted
- Jul 8, 2024
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 12 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this study is to determine the sensitivity, specificity, and positive and negative predictive values of the portable near-infrared-based device (portable NIR-based device), the InfraScanner 2500™, to detect intracranial hematomas (epidural hematomas (EDH) and/or subdural hematomas (SDH)) in patients hospitalized at Mbarara Regional Referral Hospital (MRRH) or Mayanja Memorial Hospital (MMH) who have sustained or who are suspected to have sustained head trauma.
Conditions
- Head Trauma
- Crushing Skull Injury
- Head Injury
- Head Injuries, Multiple
- Head Injuries, Closed
- Head Trauma,Closed
- Head Injury Major
- Head Injury, Minor
- Head Injury, Open
- Injury, Craniocerebral
- Injury, Head
- Multiple Head Injury
- Trauma, Head
- Head Trauma Injury
- Head Trauma, Penetrating
- Craniocerebral Injury
Interventions
InfraScanner 2500™Device
The Infrascanner is a portable screening device that uses Near-Infrared (NIR) technology to screen patients for intracranial bleeding, identifying those who would most benefit from immediate referral to a CT scan and neurosurgical intervention.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Infrascanner 2500™ Diagnostic PerformanceTime frame: Within 30 minutes following CT scan
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Mayanja Memorial Hospital
Mbarara, Uganda
1 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.